Pharmacokinetics and pharmacodynamics of mepindolol sulphate.
Five clinically healthy, male volunteers were each given an intravenous dose of 1.19 mg of 2-methyl-14C-mepindolol sulphate, followed one week later by an oral dose of 20 mg. In addition, the effect of mepindolol sulphate was studied in 3 male test subjects after repeated oral administration for 8 days with a daily dose of 2 x 2.5 mg using the heart rate behaviour model during submaximum ergometer exercise. Synchronously with pharmacodynamics, pharmacokinetic data were also obtained after multiple dosing.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000378:metabolism* / Q000494:pharmacology; D000328:Adult; D001682:Biological Availability; D001798:Blood Proteins / Q000378:metabolism; D006207:Half-Life; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010869:Pindolol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D011485:Protein Binding; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D001798:Blood Proteins; C015340:mepindolol; D010869:Pindolol